Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
McKesson
Boehringer Ingelheim
Express Scripts
Johnson and Johnson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,923,536

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,923,536 protect, and when does it expire?

Patent 7,923,536 protects ABRAXANE and is included in one NDA.

This patent has forty-two patent family members in nineteen countries.

Summary for Patent: 7,923,536
Title:Compositions and methods of delivery of pharmacological agents
Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA), Trieu; Vuong (Calabasas, CA)
Assignee: Abraxis BioScience, LLC (Los Angeles, CA)
Application Number:12/758,413
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,923,536
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,923,536

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes   Start Trial   Start Trial TREATMENT OF LUNG CANCER   Start Trial
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes   Start Trial   Start Trial TREATMENT OF PANCREATIC CANCER   Start Trial
Abraxis Bioscience ABRAXANE paclitaxel FOR SUSPENSION;IV (INFUSION) 021660-001 Jan 7, 2005 RX Yes Yes   Start Trial   Start Trial TREATMENT OF BREAST CANCER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Express Scripts
Merck
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.